Drug · CHEMBL1663
PERFLUTREN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PERFLUTREN. Drugs and targets, record CHEMBL1663. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1663
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- DMP 115, DMP-115, DMP115, FS-069, FS069, MRX-115, Perfluoropropane, Perflutren protein-type a microspheres, Perflutrene, Perflutreno
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases19
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 19Source Open Targets
See all 19 diseasesTrials82
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 12 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 26 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00625365 | A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice | Phase 4 | 1,060 | 2011-01-14 | definity | Its name | ClinicalTrials.gov |
| NCT00730964 | A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. | Phase 4 | 1,039 | 2012-06-12 | perflutren protein-type A microspheres | Its name | ClinicalTrials.gov |
| NCT00162370 | A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease | Phase 4 | 400 | 2016-12-08 | perflutren lipid microsphere | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT01490892 | Quantitative Subharmonic Breast Imaging | Phase 4 | 219 | 2020-01-13 | definity | Its name | ClinicalTrials.gov |
| NCT03719612 | DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase 3 | 160 | 2021-01-07 | definity | Its name | ClinicalTrials.gov |
| NCT03571672 | DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Phase 3 | 153 | 2020-12-17 | definity | Its name | ClinicalTrials.gov |
| NCT02764801 | Contrast-enhanced Ultrasound Evaluation of Chemoembolization | Phase 3 | 131 | 2023-09-21 | definity | Its name | ClinicalTrials.gov |
| NCT03199274 | Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer | Phase 2 | 104 | 2025-08-20 | perflutren protein-type A microspheres | Its name | ClinicalTrials.gov |
| NCT01721447 | Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage | Phase 4 | 100 | 2019-06-04 | optison | Its name | ClinicalTrials.gov |
| NCT02684435 | Contrast-enhanced Ultrasound of the Kidney | Phase 2 | 63 | 2019-07-02 | perflutren lipid | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
1 to 10 of 82
See all 82 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Group I (Perflutren Protein-type A Microspheres, CEUS) vs Group II (Standard of Care): deaths from any cause | 0 of 52 | 0 of 52 | 104 | NCT03199274 | Trial comparisons |
| Group I (Perflutren Protein-type A Microspheres, CEUS) vs Group II (Standard of Care): serious adverse events | 0 of 52 | 0 of 52 | 104 | NCT03199274 | Trial comparisons |
| For Cause vs Surveillance: Abnormal Biopsy | 10 of 20 | 7 of 20 | 40 | NCT02625428 | Trial comparisons |
| For Cause vs Surveillance: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT02625428 | Trial comparisons |
| For Cause vs Surveillance: serious adverse events | 2 of 20 | 1 of 20 | 40 | NCT02625428 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: deaths from any cause | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 4 of 8 | 9 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: Number of Participants With Clinically Significant Abnormality in Physical Examination Findings | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Body Weight Group <=40 kg: OPTISON vs Body Weight Group >40 kg: OPTISON: serious adverse events | 0 of 8 | 0 of 29 | 37 | NCT03740997 | Trial comparisons |
| Low Pulmonary Arterial Pressure vs Elevated Pulmonary Arterial Pressure: serious adverse events | 0 of 16 | 0 of 16 | 32 | NCT00918866 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials18
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1663
GET https://conductscience.org/api/drugs/v1/CHEMBL1663/trials?page=2